Analysts See $-0.34 EPS for Immune Design Corp. (IMDZ)

October 14, 2018 - By Darrin Black

Investors sentiment increased to 1.95 in 2018 Q2. Its up 0.38, from 1.57 in 2018Q1. It is positive, as 10 investors sold Immune Design Corp. shares while 12 reduced holdings. 19 funds opened positions while 24 raised stakes. 21.34 million shares or 1.26% less from 21.61 million shares in 2018Q1 were reported.
Ecor1 Cap Limited Company invested in 1.92% or 4.44M shares. D E Shaw owns 18,170 shares. Alliancebernstein Limited Partnership reported 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Art Advisors Limited Liability Company holds 33,067 shares or 0.01% of its portfolio. Northern Tru invested in 0% or 357,880 shares. 4.16M were accumulated by Bvf Il. Ameritas Partners holds 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ) for 2,948 shares. Savings Bank Of America De holds 0% in Immune Design Corp. (NASDAQ:IMDZ) or 46,754 shares. Moreover, Walleye Trading Limited Liability Corporation has 0% invested in Immune Design Corp. (NASDAQ:IMDZ). Personal Advisors Corp has invested 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Proquest Iv Limited reported 1.24M shares. Wells Fargo Mn holds 0% in Immune Design Corp. (NASDAQ:IMDZ) or 146,229 shares. Thompson Davis Incorporated reported 250 shares. Essex Investment Mngmt Limited Liability stated it has 42,179 shares. Tiverton Asset Mgmt Llc holds 0.01% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ) for 38,675 shares.

Analysts expect Immune Design Corp. (NASDAQ:IMDZ) to report $-0.34 EPS on November, 7.They anticipate $0.18 EPS change or 34.62 % from last quarter’s $-0.52 EPS. After having $-0.29 EPS previously, Immune Design Corp.’s analysts see 17.24 % EPS growth. The stock decreased 33.69% or $0.94 during the last trading session, reaching $1.85. About 3.30 million shares traded or 1075.98% up from the average. Immune Design Corp. (NASDAQ:IMDZ) has declined 66.33% since October 14, 2017 and is downtrending. It has underperformed by 81.95% the S&P500.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company has market cap of $89.11 million. It primarily develops oncology product candidates based on its ZVex and GLAAS product discovery platforms. It currently has negative earnings. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma.

More notable recent Immune Design Corp. (NASDAQ:IMDZ) news were published by: Streetinsider.com which released: “After-Hours Stock Movers 10/11: (CORI) (TTPH) (PGNX) Higher; (TRVN) (IMDZ) Lower (more…)” on October 11, 2018, also Nasdaq.com with their article: “Mid-Afternoon Market Update: Corium Surges On Acquisition News; Immune Design Shares Slide” published on October 12, 2018, Streetinsider.com published: “Pre-Open Movers 10/12: (CORI) (TTPH) (SQ) Higher; (IMDZ) (TRVN) Lower (more…)” on October 12, 2018. More interesting news about Immune Design Corp. (NASDAQ:IMDZ) were released by: Seekingalpha.com and their article: “Immune Design: Can This Small Oncology Play Deliver?” published on September 18, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: October 12, 2018.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>